Professional Documents
Culture Documents
Public Health
TH Tulchinsky MD MPH
Braun School of Public Health
Dec 2008
1
Licensed Vaccines in Routine Use in the United States, 1980 and 2008
2
Smith, J. C. et. al. Ann Intern Med 2009;150:45-49
3
Vaccine Preventable Deaths and the Global
Immunization Vision and Strategy, 2006-2015
• Priorities in PH interventions
• VPD deaths can be averted if existing vaccines used at full
potential
• 2002 deaths from diseases for which vaccines are WHO
recommended
• <1,000 children <5 died from polio;
• 4,000 children died from diphtheria;
• 15,000 children died from yellow fever;
• 198,000 children died from tetanus;
• 294,000 children died from pertussis;
• 386,000 children died from (Hib) Hemophilus influenzae type b);
• 540,000 children died from measles
4
5
6
Vaccination and Prevention
9
Preparation of Vaccines I
11
Introduction of first generation of vaccines for
use in humans
Originals After World War II
13
Vaccine Preventable Diseases (VPDs)
• World immunization coverage up from 10% in
1970s to 80% in 1990s, then to 77% in 2004
• Smallpox eradication achieved 1982
• Polio eradication 2005-2010
• Measles still kills >0.4 million per year, need for a
two dose policy (MMR)
• Many new vaccines available and coming
• Costs effectiveness and priorities
• Reinforce success e.g. Sanipeds in former USSR
• Coverage is good; Adapt and expand 14
Vaccination Issues
• Political support • Strategies
• Professional recognition • Select target groups
• Financing • Coverage
• Expanding vaccine • Herd immunity
capability • Cold chain and logistics
• Organization, delivery, • Continuous up-dating
follow up • International and “gold
• Reporting “up and down standards”
and sideways” (UDS) • Infectious and chronic
• Program content diseases
15
New Vaccines and Combinations
• Hepatitis B (and A) catch up
• Haemophilus influenza b (Hib) - universal
• MMR, Measles, mumps, rubella x 2 - universal
• DPT x 4 - update policies, catch up and adult boosters -
• Varicella and catch up, also for elderly (H Zoster)
• Influenza – all ages
• Pneumococcal pneumonia – all ages
• Rotavirus
• Human Papilloma Virus (HPV) and cancer cervix
• Future vaccines – streptococcus, cytomegalovirus (CMV),
helicobacter, HIV, malaria, avian flu
• Cocktails – maximum combination of routine vaccines
• New methods of production of vaccines 16
Vaccines by Period of Development
Eighteenth century: Smallpox (1798)
Nineteenth century: Rabies, Hog cholera, Diphtheria antitoxin,
Cholera, Plague, Typhoid (1896)
Early twentieth century: BCG tuberculosis, Pertussis (1926)
Diphtheria (1923), (1927) Influenza (1936) Tetanus toxoid (1927),
Yellow fever (1935) Rickettsia (1936), Influenza A (1936)
Post-World War II: Yellow fever (1953) Influenza (1945) Diphtheria
toxoid (1949), Tetanus toxoid (1949), Pneumococcus (1976-83),
Typhoid (1952), Polio Salk (1955), Meningococcus (1962), Polio,
Sabin (1963), Measles (1963), Mumps (1967), Tick-borne
encephalitis Rubella (1970), Anthrax (1970), MMR (1971)
1980–1999: Adenovirus, Rabies, (1980, human), Hemophilus influenz
b, Hepatitis B (1987) Typhoid (1992), salmonella, Japanese
encephalitis, Hepatitis B (1981), Varicella (1995), Pertussis
acellular (1993), Lyme disease (1998) Hepatitis A (1995), Rotavirus
(1998)
2000–2010: Pneumococcal, meningococcal disease, influenza,
parainfluenza, human papillomavirus (HPV)
Future: H. pylori,, streptocococcus, HIV, hepatitis C, adenoviruses 17
“Drug company chief urges faster introduction
of new vaccines in poor nations”
• Head of GlaxoSmithKline urges faster introduction of new life
saving vaccines in poor countries; avoid customary lengthy
delays.
• Many new vaccines are becoming a reality against rotavirus,
pneumococcal disease, and cervical cancer
• “These vaccines are there, so it’s important to introduce them
today in developing countries and not 20 years later.”
• With the exception of the rotavirus vaccine, introduced in
Latin America and Europe at the same time, so far vaccines
had been introduced in developing countries 10-20 years after
developed countries had received them.
• What we expect now is that these vaccines be introduced in
the poorest countries. “The money is there, the science is
there.”
18
BMJ 2006;333:11 (1 July).
Target Groups
• Newborns - Hep B, DPT, Polio, BCG
• Infants – Hep B, DPT, Polio (IPV, OPV), Hib, Hep A,
MMR, pneumococcal pneumonia, influenza, rotavirus
• Pre-schoolers –catch up
• School age children - dT, MMR
• Teen agers – catch up Hep B, MMR
• Adult women - Rubella
• Chronically ill – Influenza, pneumococcal pneumonia
• Travelers – yellow fever, polio, dT
• Adults - dT
• Elderly - Influenza, pneumococcal pneumonia, dT
• Risk groups for bioterrorism – smallpox, anthrax 19
Tetanus incidence per 100000
0.3
0.25
0.2
Denmark
Israel
0.15 Russian Federation
United Kingdom
Uzbekistan
0.1
0.05
0 20
1970 1980 1990 2000 2010
Pertussis incidence per 100000
400
300
Denmark Denmark
Israel
200 Russian Federation
United Kingdom
Uzbekistan
UK
100
0 21
1970 1980 1990 2000 2010
Congenital rubella incidence per 100000
0.15
Denmark
Israel
0.1
Denmark
Israel
Russian Federation
United Kingdom
Uzbekistan
0.05
UK
0 22
1980 1985 1990 1995 2000 2005 2010
Rubella incidence per 100000
1000
900 Israel
800
700
UK
600
Denmark
Israel
500 Russian Federation
United Kingdom
Uzbekistan
400
300
200
100
0 23
1970 1980 1990 2000 2010
Diphtheria incidence per 100000
30
25
Russia
20
Israel
Russian Federation
15 Turkey
United Kingdom
Uzbekistan
10
0 24
1970 1980 1990 2000 2010
Tuberculosis incidence per 100000
100
Russia
90
80
Uzbekistan
70
60
Israel
Russian Federation
50 Turkey
United Kingdom
Uzbekistan
40
Turkey
30
20
UK
10
0
Israel 25
1970 1980 1990 2000 2010
Viral hepatitis B incidence per 100000
50
40
30
Finland
Israel
Russian Federation
United Kingdom
20
Russia
10
0 26
1985 1990 1995 2000 2005 2010
Hospital discharges, infectious and
parasitic diseases per 100000
1500
1000
Finland
Israel
Russian Federation
United Kingdom
500
0 27
1985 1990 1995 2000 2005 2010
Clinically diagnosed AIDS incidence per 100000
4
Finland
Israel
2 Russian Federation
United Kingdom
0 28
1970 1980 1990 2000 2010
Haemophilius influenza type b invasive
disease incidence per 100000
2.5
1.5
Finland
Israel
Russian Federation
United Kingdom
0.5
0 29
1990 1995 2000 2005 2010
CDC Recommended Immunization Schedule,
0 to 6 years, US, 2009
30
WHO 1998 Targets of Infectious Disease
Eradication / Control
31
Criteria for Assessing Eradicability of Diseases:
International Task Force for Disease Eradication
• Scientific Feasibility
– Epidemiologic vulnerability; lack of non-human reservoir, ease of
spread, no natural immunity, relapse potential;
– Effective practical intervention available; vaccine or other
primary preventive or curative treatment, or vectoricide that is
safe inexpensive, long lasting and easily used in the field;
– Demonstrated feasibility of elimination in specific locations, such
as an island or other geographic unit.
• Political Will/Popular Support
– Perceived burden of the disease; morbidity, mortality, disability
and costs of care in developed and developing countries;
– Expected cost of eradication;
– Synergy of implementation with other programs;
– Reasons for eradication versus control.
CDC. International Task Force for Disease Eradication. MMWR.1992;41:40-2 32
Eradication or Control of VPDs
Since eradication of smallpox, discussion of possibility of eradicating
other diseases
Potential candidate diseases emerged; some abandoned because of
practical difficulties with current technology
Diseases under discussion for eradication - measles, TB, and some
tropical diseases e.g. malaria and dracunculiasis
Eradication - no further cases of a disease occur anywhere in nature;
continued control measures may be unnecessary e.g. smallpox,
polio (?)
Reducing epidemic and endemic VPDs in selected areas or target
groups, and achieve local elimination
Local elimination is where domestic circulation of a virus is
interrupted with cases occurring from importation only
Strong, sustained immunization program, adaptation to changing
epidemiologic patterns e.g. age groups, importation
33
Risk Groups Recommended for Annual
Influenza Vaccination, 2005
• All persons aged >65 years (or 55);
• Nursing homes and other chronic-care facility residents of any age
who have chronic medical conditions;
• Adults and children with chronic disorders of the pulmonary or
cardiovascular systems, including asthma;
• Adults and children in medical follow-up or hospitalization during
preceding year for chronic metabolic diseases (e.g. diabetes mellitus),
renal dysfunction, hemoglobinopathies, immunosuppression (by
medications or by HIV); or with conditions (e.g. cognitive
dysfunction, spinal cord injuries, seizures or other neuromuscular
disorders) which compromise respiratory function;
• Children, adolescents (aged 6 months--18 years) on long-term aspirin
therapy and, therefore at risk for Reye syndrome after influenza;
• Women who will be pregnant during the influenza season; and
• Children aged 6--23 months.
Source: CDC. Prevention and Control of Influenza. Recommendations of the Advisory Committee
34
on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2005;54(RR);1-40
Infant, Child and Adolescent
Immunization Schedule US CDC, MMWR. 2006
35
Recommended Adult Immunization Schedule, United States, 2002-2003 Recommended Immunizations for Adults with Medical Conditions, United States, 2002-2003
For all persons in this Catch-up on For persons with For all persons in Catch-up on For persons with
this group childhood vaccinations medical / exposure indications Contraindicated
age group childhood vaccinations medical / exposure indications
Age Vaccine
19-49 years 50-64 years 65 years and older Tetanus- Influenza Pneumo- Hepatitis Hepatitis Measles Varicella*
Vaccine Diphtheria coccal A Mumps
B*
(Td)* (poly- Rubella
Medical saccharide) (MMR)*
Tetanus, Diphtheria 1 dose booster every 10 years1
(Td)* Conditions
Pregnancy A
1 dose annually for persons
with medical or occupational
Influenza indications, or household contacts 1 annual dose
of persons with indications 2 Diabetes, heart disease,
chronic pulmonary disease,
chronic liver disease, B C D
including chronic alcoholism
1 dose for unvaccinated persons 3
Pneumococcal 1 dose for persons with medical or other indications. (1 dose
(polysaccharide) revaccination for immunosuppressive conditions) 3,4
1 dose revaccination 4
Congenital immunodeficiency,
leukemia, lymphoma,
generalized malignancy,
Hepatitis B* 3 doses (0, 1-2, 4-6 months) for persons with medical, behavioral, occupational, or other indications 5 therapy with alkylating agents, E F
antimetabolites, radiation
or large amounts
of corticosteroids
Hepatitis A 2 doses (0, 6-12 months) for persons with medical, behavioral, occupational, or other indications 6
Meningococcal
1 dose for persons with medical or other indications 9 HIV infection E, J K
(polysaccharide)
See Footnotes for Recommended Adult Immunization Schedule on the back cover. *Covered by the Vaccine Injury Compensation Program.
36
*Covered by the Vaccine Injury Compensation Program. For information on how to file a claim call 1-800-338-2382. Please also visit http://www.hrsa.osp.gov/vicp accessed A. If pregnancy is at 2nd or 3rd trimester during influenza season. G. Hemodialysis patients: Use special formulation of vaccine (40 ug/mL) or two 1.0
February 21, 2002. To file a claim for vaccine injury write: U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington D.C. 20005. (202) 219-9657. B. Although chronic liver disease and alcoholism are not indicator mL 20 ug doses given at one site. Vaccinate early in the course of renal disease.
Bacterial Diseases
37
Viral Diseases
Eradicable- Regional/Global
Poliomyelitis
Measles
Rubella
Mumps
Varicella
38
Non Infectious Disease
Source: Global Disease Elimination and Eradication as Public Health Strategies: Proceedings39of a
Conference Atlanta, Georgia, USA, 1998. Bull WHO. 1998;76 Supplement 2:1-161
WHO on New Vaccines, 2006
Six traditional vaccines against tuberculosis (BCG),
diphtheria, tetanus, pertussis, polio (OPV) and measles for
their regular infant immunization schedule have contributed
to the prevention of millions of unnecessary deaths.
Many vaccines exist and are increasingly offered to all
infants in many countries allowing for additional prevention
of untimely deaths and disabilities.
Those include vaccines against yellow fever, rubella, hepatitis
B, invasive haemophilus influenzae type b (Hib) disease and
Japanese encephalitis.
In order to achieve the Millennium Development Goal of
reducing child mortality, the expanded use of those new
vaccines will be necessary.
40
New Vaccines-New Issues
• Pneumcoccus
• Lyme disease
• Rotavirus
• Human Papilloma Virus • Western Equine
Encephalitis
• HIV
• Malaria • Ebola virus
• Dengue • Leishmaniasis
• Salmonella • Helicobacter pylori
• Eschericia coli • Many others
41
Vaccination and Decline of Hib diseases
in Finland
200 1986- Vaccination
PRP-D, PRP-CRM, PRP-T
180
160
Number of cases
140
120 0-4yr
100 olds
80 >=5 yr
60 olds
40
20
0
8
82
2
6
88
84
86
6
80
90
9
7
9
19
19
19
19
19
19
19
19
19
19
19
Year 42
% of childhood meningitis caused by Hib in
four regions in Russia (Oct 1996 - Nov 1997)*
Lunina E, 2003
50%
40%
Moscow
30%
St Petersburg
Ekaterinburg
20% 50%
31% 36% 30% Arkhangelsk
10%
0%
• Anthrax
• Smallpox
• Tularemia
• Hemorrhagic fevers e.g. Rift Valley Fever, others
• Polio
CDC. Biological and Chemical
Terrorism: Strategic Plan for
Preparedness and Response
Recommendations of the CDC
NEJM. 2002;346:1262-1263 Strategic Planning Workgroup.
Smallpox and Bioterrorism MMWR. 2000;49 (RR04)1-14.
47
SAGE on Haemophilus influenza b (Hib)
48
WER Nov 24, 2006
Influenza Vaccine
49
Current Policy Considerations
• BCG – for infants only (if at all)
• Varicella – to eradicate
• MMR to eradicate measles, mumps and rubella
and rubella syndrome
• Haemophilus influenza B recommended
• Hepatitis B with catchup of children, teens,
adults, health workers
• Influenza and pneumonia vaccination for all
children
• Rotavirus vaccine for all children
• Hepatitis A for endemic areas
• Adult diphtheria, pertussis and tetanus
50
WHO/UNICEF
51
52
Vaccines administered simultaneously:
combination vaccines
• Combination vaccines needed to fill epidemiologic niches
in EPI with, e.g. a measles-yellow fever, a measles-
Japanese encephalitis or a pertussis-based paediatric
combination rabies vaccine
• Other combinations could broaden protection against the
pathogens responsible for meningitis, pneumonia, or
enteric diseases
• Complex of issues – necessity, feasibility, affordability will
determine future combinations of vaccines
55
Key Sources
56
57